BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO

BridgeBio Pharma Stock Analysis & Ratings

BBIO Stock Chart & Stats

Day’s Range$7.25 - $7.64
52-Week Range$4.98 - $65.33
Previous Close$7.61
Volume1.16M
Average Volume (3M)2.55M
Market Cap$1.08B
P/E Ratio-1.8
Beta1.19
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-4.08


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BBIO FAQ

What was BridgeBio Pharma’s price range in the past 12 months?
BridgeBio Pharma lowest stock price was $4.98 and its highest was $65.33 in the past 12 months.
    What is BridgeBio Pharma’s market cap?
    BridgeBio Pharma’s market cap is $1.08B.
      What is BridgeBio Pharma’s price target?
      The average price target for BridgeBio Pharma is $23.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $32.00 ,the lowest forecast is $17.00. The average price target represents 216.76% Increase from the current price of $7.34.
        What do analysts say about BridgeBio Pharma?
        BridgeBio Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is BridgeBio Pharma’s upcoming earnings report date?
          BridgeBio Pharma’s upcoming earnings report date is Aug 16, 2022 which is in 84 days.
            How were BridgeBio Pharma’s earnings last quarter?
            BridgeBio Pharma released its earnings results on May 05, 2022. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$1.086 by -$0.264.
              Is BridgeBio Pharma overvalued?
              According to Wall Street analysts BridgeBio Pharma’s price is currently Undervalued.
                Does BridgeBio Pharma pay dividends?
                BridgeBio Pharma does not currently pay dividends.
                What is BridgeBio Pharma’s EPS estimate?
                BridgeBio Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does BridgeBio Pharma have?
                BridgeBio Pharma has 147,690,000 shares outstanding.
                  What happened to BridgeBio Pharma’s price movement after its last earnings report?
                  BridgeBio Pharma reported an EPS of -$1.35 in its last earnings report, missing expectations of -$1.086. Following the earnings report the stock price went down -12.471%.
                    Which hedge fund is a major shareholder of BridgeBio Pharma?
                    Among the largest hedge funds holding BridgeBio Pharma’s share is Perceptive Advisors LLC. It holds BridgeBio Pharma’s shares valued at 39M.

                      ---

                      BridgeBio Pharma Stock Analysis

                      The BridgeBio Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      BridgeBio Pharma Inc

                      BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Karuna Therapeutics
                      Turning Point Therapeutics
                      Akero Therapeutics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis